Abstract
One aim of stem cell-based therapy is to utilize pluripotent stem cells (PSCs) as a supplementary source of cells to repair or replace tissues or organs that have ceased to function due to severe tissue damage. However, PSC-based therapy requires extensive research to ascertain if PSC derivatives are functional without the risk of tumorigenicity, and also do not engender severe immune rejection that threatens graft survival and function. Recently, the suitability of induced pluripotent stem cells applied for patient-tailored cell therapy has been questioned since the discovery of several genetic and epigenetic aberrations during the reprogramming process. Hence, it is crucial to understand the effect of these abnormalities on the immunogenicity and survival of PSC grafts. As induced PSC-based therapy represents a hallmark for the potential solution to prevent and arrest immune rejection, this review also summarizes several up-to-date key findings in the field.
Keywords: Differentiation, epigenetic, genetic, immunogenicity, pluripotent stem cell, MHC I, MHC II, NK cell, T cell.
Current Stem Cell Research & Therapy
Title:Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Volume: 9 Issue: 1
Author(s): Yuan Tan, Sarah Ooi and Lisheng Wang
Affiliation:
Keywords: Differentiation, epigenetic, genetic, immunogenicity, pluripotent stem cell, MHC I, MHC II, NK cell, T cell.
Abstract: One aim of stem cell-based therapy is to utilize pluripotent stem cells (PSCs) as a supplementary source of cells to repair or replace tissues or organs that have ceased to function due to severe tissue damage. However, PSC-based therapy requires extensive research to ascertain if PSC derivatives are functional without the risk of tumorigenicity, and also do not engender severe immune rejection that threatens graft survival and function. Recently, the suitability of induced pluripotent stem cells applied for patient-tailored cell therapy has been questioned since the discovery of several genetic and epigenetic aberrations during the reprogramming process. Hence, it is crucial to understand the effect of these abnormalities on the immunogenicity and survival of PSC grafts. As induced PSC-based therapy represents a hallmark for the potential solution to prevent and arrest immune rejection, this review also summarizes several up-to-date key findings in the field.
Export Options
About this article
Cite this article as:
Tan Yuan, Ooi Sarah and Wang Lisheng, Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives, Current Stem Cell Research & Therapy 2014; 9 (1) . https://dx.doi.org/10.2174/1574888X113086660068
DOI https://dx.doi.org/10.2174/1574888X113086660068 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Imaging Techniques in Acute Kidney Injury
Current Drug Targets A Review of Agents Patented for their Neuroprotective Properties
Recent Patents on CNS Drug Discovery (Discontinued) CYLD-Mediated Signaling and Diseases
Current Drug Targets Anti-Diabetic Effects of Isolated Lipids from Natural Sources through Modulation of Angiogenesis
Current Molecular Pharmacology Anti-Allergic and Antioxidant Activity of 5-Hydroxy-3,6,7,3’,4’- Pentamethoxy Flavone Isolated from Leaves of Vitex negundo
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Experimental Brain Ischemic Preconditioning: A Concept to Putative Targets
CNS & Neurological Disorders - Drug Targets Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Myogenic Tone as a Therapeutic Target for Ischemic Stroke
Current Vascular Pharmacology Therapeutic Potential of High Mobility Group Box-1 in Ischemic Injury and Tissue Regeneration
Current Vascular Pharmacology Gastric Mucosal Protection And Central Nervous System
Current Pharmaceutical Design Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design OPA1 in Cardiovascular Health and Disease
Current Drug Targets Cellular and Physiological Effects of Arginine
Mini-Reviews in Medicinal Chemistry Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease
Current Pharmaceutical Design Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes Mellitus
Current Neuropharmacology